Alpha-blockers and congestive heart failure: Early termination of an arm of the ALLHAT trial

Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension, Cleveland Clinic; member, Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A101,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Vidt has indicated that he has received grant or research support from the Searle, Astra-Zeneca, and Novartis companies and serves on the speakers' bureaus of the Astra-Zeneca, Merck, Novartis, and Solvay companies, all of which make antihypertensive agents.

Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension, Cleveland Clinic; member, Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A101,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Vidt has indicated that he has received grant or research support from the Searle, Astra-Zeneca, and Novartis companies and serves on the speakers' bureaus of the Astra-Zeneca, Merck, Novartis, and Solvay companies, all of which make antihypertensive agents.

Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension, Cleveland Clinic; member, Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A101,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195

Dr. Vidt has indicated that he has received grant or research support from the Searle, Astra-Zeneca, and Novartis companies and serves on the speakers' bureaus of the Astra-Zeneca, Merck, Novartis, and Solvay companies, all of which make antihypertensive agents.